These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16763468)

  • 1. Safety of gadobenate dimeglumine (MultiHance): Summary of findings from clinical studies and postmarketing surveillance.
    Shellock FG; Parker JR; Venetianer C; Pirovano G; Spinazzi A
    Invest Radiol; 2006 Jun; 41(6):500-9. PubMed ID: 16763468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Multicenter analysis of tolerance and clinical safety of the extracellular MR contrast agent gadobenate dimeglumine (MultiHance)].
    Herborn CU; Jäger-Booth I; Lodemann KP; Spinazzi A; Goyen M
    Rofo; 2009 Jul; 181(7):652-7. PubMed ID: 19291607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance.
    Voth M; Rosenberg M; Breuer J
    Invest Radiol; 2011 Nov; 46(11):663-71. PubMed ID: 21623211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use.
    Knopp MV; Balzer T; Esser M; Kashanian FK; Paul P; Niendorf HP
    Invest Radiol; 2006 Jun; 41(6):491-9. PubMed ID: 16763467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.
    Knopp MV; Runge VM; Essig M; Hartman M; Jansen O; Kirchin MA; Moeller A; Seeberg AH; Lodemann KP
    Radiology; 2004 Jan; 230(1):55-64. PubMed ID: 14695387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac electrophysiologic monitoring after injection of gadobenate dimeglumine versus placebo in healthy volunteers and patients with cardiovascular disease.
    Pirovano G; Goodman DB; Halemane U; Venetianer C; Kirchin MA; Spinazzi A
    Radiology; 2004 Nov; 233(2):555-65. PubMed ID: 15375224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety characteristics of gadobenate dimeglumine: clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine.
    Shellock FG; Parker JR; Pirovano G; Shen N; Venetianer C; Kirchin MA; Spinazzi A
    J Magn Reson Imaging; 2006 Dec; 24(6):1378-85. PubMed ID: 17078095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety assessment of gadobenate dimeglumine (MultiHance): extended clinical experience from phase I studies to post-marketing surveillance.
    Kirchin MA; Pirovano G; Venetianer C; Spinazzi A
    J Magn Reson Imaging; 2001 Sep; 14(3):281-94. PubMed ID: 11536405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections.
    Abujudeh HH; Kosaraju VK; Kaewlai R
    AJR Am J Roentgenol; 2010 Feb; 194(2):430-4. PubMed ID: 20093606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Objective evaluation of acute adverse events and image quality of gadolinium-based contrast agents (gadobutrol and gadobenate dimeglumine) by blinded evaluation. Pilot study.
    Semelka RC; Hernandes Mde A; Stallings CG; Castillo M
    Magn Reson Imaging; 2013 Jan; 31(1):96-101. PubMed ID: 22898688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine.
    Bauner KU; Reiser MF; Huber AM
    Invest Radiol; 2009 Feb; 44(2):95-104. PubMed ID: 19077911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of immediate gadolinium contrast media reactions.
    Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
    AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaphylaxis to gadobenate dimeglumine (Multihance): a case report.
    Kalogeromitros DC; Makris MP; Aggelides XS; Spanoudaki N; Gregoriou SG; Avgerinou G; Rigopoulos DG
    Int Arch Allergy Immunol; 2007; 144(2):150-4. PubMed ID: 17536224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine.
    Bleicher AG; Kanal E
    AJR Am J Roentgenol; 2008 Dec; 191(6):W307-11. PubMed ID: 19020220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.
    Bryant BJ; Im K; Broome DR
    Clin Radiol; 2009 Jul; 64(7):706-13. PubMed ID: 19520215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
    Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
    AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse Reactions to Gadoterate Meglumine: Review of Over 25 Years of Clinical Use and More Than 50 Million Doses.
    de Kerviler E; Maravilla K; Meder JF; Naggara O; Dubourdieu C; Jullien V; Desché P
    Invest Radiol; 2016 Sep; 51(9):544-51. PubMed ID: 27504794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute side effects of three commonly used gadolinium contrast agents in the paediatric population.
    Neeley C; Moritz M; Brown JJ; Zhou Y
    Br J Radiol; 2016 Jul; 89(1063):20160027. PubMed ID: 27194459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse allergic reactions to linear ionic gadolinium-based contrast agents: experience with 194, 400 injections.
    Aran S; Shaqdan KW; Abujudeh HH
    Clin Radiol; 2015 May; 70(5):466-75. PubMed ID: 25626627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced magnetic resonance angiography of the supraaortic vessels at 3 Tesla.
    Bueltmann E; Erb G; Kirchin MA; Klose U; Naegele T
    Invest Radiol; 2008 Oct; 43(10):695-702. PubMed ID: 18791411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.